2013
Acne Vulgaris
Sponsor: Braintree Laboratories
BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris
Phase: Phase 2
Start Date: February 2013
End Date: Date Here
Psoriasis
Sponsor: Maruho North America Inc.
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
Phase: Phase 3
Start Date: June 2013
End Date: April 2015
Plaque Psoriasis
Sponsor: Therapeutics, Inc.
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
Phase: Phase 3
Start Date: June 2013
End Date: March 2014
Chronic Pruritus
Sponsor: Menlo Therapeutics Inc.
VPD-737 for Treatment of Chronic Pruritus
Phase: Phase 2
Start Date: October 2013
End Date: April 2015
Atopic Dermatitis
Sponsor: Regeneron Pharmaceuticals | Sanofi
Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis
Phase: Phase 3
Start Date: October 2013
End Date: December 2018
Acne Vulgaris
Sponsor: Cadila Healthcare Limited
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
Phase: Phase 3
Start Date: November 2013
End Date: September 2016
Psoriasis
Sponsor: Promius Pharma, LLC
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Phase: Phase 3
Start Date: November 2013
End Date: January 2015
Plaque Type Psoriasis
Sponsor: Sandoz | Hexal AG
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira
Phase: Phase 3
Start Date: December 2013
End Date: February 2016